Dr. Reddy's Laboratories Limited filings document its U.S. reporting as a foreign private issuer with American depositary receipts listed on the New York Stock Exchange. Recent Form 6-K reports furnish exchange intimations and exhibits submitted to Indian exchanges and the NYSE, including board-meeting notices and other current-report disclosures.
The filing record centers on Rule 13a-16 and 15d-16 submissions, Form 20-F reporting status, governance communications, and public-company notices tied to Dr. Reddy's pharmaceutical operations and securities across India and the United States.
Dr. Reddy’s Laboratories (RDY) received approval from India’s Central Drugs Standard Control Organisation under the Drugs Controller General of India for Zytorvi (toripalimab) with cisplatin and paclitaxel as first-line treatment for adults with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC). This is Zytorvi’s second approved indication in India, following nasopharyngeal carcinoma, and the ESCC indication does not require patient selection based on PD-L1 expression.
The Phase 3 JUPITER-06 trial supporting the approval reported a 42% reduction in the risk of disease or death versus chemotherapy alone. At final overall-survival analysis, median overall survival was 17.7 months with toripalimab plus chemotherapy and 12.9 months with chemotherapy alone; clinical benefit was observed across PD-L1-expression subgroups. Under a 2023 licensing and commercialization agreement with Shanghai Junshi Biosciences Co., Ltd., Dr. Reddy’s holds exclusive rights to develop and commercialize toripalimab in 21 countries.
In India, esophageal cancer was the fourth leading cause of cancer-related death in 2024, accounting for approximately 8.1% of cancer deaths. ESCC accounts for approximately 80% of esophageal cancer cases in India.
Dr. Reddy’s Laboratories Limited reported that the USFDA completed a Pre-Approval Inspection at its FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh. The inspection ran from October 8, 2026, to October 9, 2026. The agency issued a Form 483 with three observations, which the company said it will address within the stipulated timeline.
Dr. Reddy’s Laboratories Limited reported that the USFDA completed a Pre-Approval Inspection at its FTO-11 manufacturing facility in Pydibhimavaram, Andhra Pradesh, from October 5 to October 7, 2026. The USFDA issued a Form 483 with two observations.
DR. REDDY’S LABORATORIES LIMITED will announce results for the quarter and six months ended September 30, 2026, on Friday, October 23, 2026, after the Board Meeting. The company will host an earnings call that day at 19:30 PM IST / 10:00 AM ET to discuss its financial performance. The press-meet presentation, and the call’s audio and transcript, will be available on the company’s website.
Dr. Reddy’s Laboratories Limited disclosed that its step-down wholly owned subsidiary, Dr. Reddy’s Laboratories, Inc., received an IRS transcript on October 2, 2026, dated September 25, 2026, classifying $32,350.20 as a penalty for misclassifying the fiscal-year reference when making a tax payment. The company assessed the penalty as having no material impact on its financials, operations or other activities.
DR REDDYS LABORATORIES LTD (RDY) reports that its Board of Directors will meet on October 23, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter ending September 30, 2026. Under SEBI insider trading rules, the trading window for the company’s securities is closed from September 24, 2026 to October 25, 2026, both days inclusive.
Dr. Reddy’s Laboratories Limited (RDY) reports that its management will participate in an investor conference organized by Nomura in Hyderabad on September 25, 2026. The meeting will be an in-person group meet with analyst and institutional investors, scheduled from 11:00 to 14:00 IST and is subject to change due to exigencies of the investors or the company.
DR REDDYS LABORATORIES LTD (RDY) has entered into an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India Private Limited for QDENGA, Takeda’s dengue vaccine, in India’s private market. Dr. Reddy’s will exclusively distribute and promote QDENGA for pediatric and adult vaccination in the private market, while Takeda will retain commercialization rights in the public market, and will handle manufacturing and importation of the vaccine. The arrangement involves no upfront consideration or milestone payments; other commercial terms are confidential. QDENGA received marketing authorization from India’s Central Drugs Standard Control Organization in July 2026 for individuals aged 4–60 years and, subject to applicable local processes, is anticipated to be available in the first half of 2027. The collaboration aligns with Dr. Reddy’s strategy to strengthen its vaccines business in India and is positioned to support broader public-health efforts against dengue.
DR REDDYS LABORATORIES LTD (RDY) reports that the U.S. Food and Drug Administration completed a records assessment under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act at its API manufacturing facility, Industrias Químicas Falcón de México, S.A. de C.V., in Jiutepec, Morelos, Mexico. The assessment took place between July 17, 2026 and September 8, 2026. At the conclusion, the FDA issued a Form FDA 2953 with two observations, and the company states it will respond within the stipulated timeline.
DR REDDYS LABORATORIES LTD (RDY) reports as a foreign private issuer on Form 6-K that its management plans to participate in upcoming analyst and institutional investor meetings. The company will attend investor conferences organized by ICICI Securities on September 17, 2026 in Hyderabad and by Bank of America on September 24, 2026 via a virtual format.
Both meetings are scheduled as group meetings, with the ICICI Securities session from 12:30 to 13:30 IST and the Bank of America session from 14:00 to 15:00 IST. The company notes that this schedule may change due to exigencies on the part of investors or the company.